rasburicase (SR29142)

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Nutritional and Metabolic Diseases

Conditions

Nutritional and Metabolic Diseases

Trial Timeline

Jun 1, 2005 → Apr 1, 2006

NCT ID

NCT00290992

About rasburicase (SR29142)

rasburicase (SR29142) is a phase 2 stage product being developed by Sanofi for Nutritional and Metabolic Diseases. The current trial status is completed. This product is registered under clinical trial identifier NCT00290992. Target conditions include Nutritional and Metabolic Diseases.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00290992	Phase 2	Completed	Jun 1, 2005	Apr 1, 2006	Nutritional and Metabolic Diseases
NCT00230217	Approved	Completed	Mar 1, 2004	Jul 1, 2006	Tumors
NCT00631579	Phase 2	Completed	Apr 1, 2003	Jun 1, 2004	Hyperuricemia
NCT00664144	Phase 2	Terminated	Jul 1, 2002	Jan 1, 2005	Hyperuricemia

Competing Products

2 competing products in Nutritional and Metabolic Diseases

See all competitors

Product	Company	Stage	Hype Score
ClinOleic (Baxter Healthcare, Deerfield, IL, USA)	Baxter	Phase 1	30
stannsoporfin	Mallinckrodt Pharmaceuticals	Phase 3	69

Other Products from Sanofi

Adacel®Approved

LACTIC ACID(ND)Approved

DupilumabApproved

glatiramer acetateApproved

INSULIN GLULISINE + INSULIN GLARGINEApproved